ArticleJournal of computer-aided molecular design2025
Predicting drug-target affinity through triple pre-activated random residual planet convolution coupled attention network and contact maps.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery relies on the ability to predict drug-target affinity (DTA), which allows for the efficient identification of drug candidates for certain protein targets. Scalability, accuracy, and interpretability are issues that traditional methods must deal with. In order to improve prediction accuracy, this study proposes a sophisticated approach that combines contact map representations with the Triple Pre-Activated Random Residual Planet Convolution Attention Network (Tri-Pre-A2RP-2CAN). The DTA, KIBA, and Davis datasets are the sources of the input data. Preprocessing employs Focal Vision Transformer with a Gabor Filter for feature enhancement. Feature extraction uses a Dual-Aggregation Transformer (DAT) to capture complex molecular and protein patterns. The modeling framework incorporates Tri-Pre-A2RP-2CAN and RCNN, optimized with PACRTAMN architecture and Planet optimization based hyperparameter tuning. This innovative approach achieves 99.9% accuracy, outperforming existing methods in modeling drug-target interactions. It enhances DTA prediction, improves molecular interaction analysis, and optimizes drug discovery processes, offering scalable and interpretable solutions for pharmaceutical advancements.
Indexed as
Identifiers
41055858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.